Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury.

Heery CR, Palena C, McMahon S, Donahue RN, Lepone LM, Grenga I, Dirmeier U, Cordes L, Marté J, Dahut W, Singh H, Madan RA, Fernando RI, Hamilton DH, Schlom J, Gulley JL.

Clin Cancer Res. 2017 Nov 15;23(22):6833-6845. doi: 10.1158/1078-0432.CCR-17-1087. Epub 2017 Aug 30.

PMID:
28855356
2.

Identification and characterization of enhancer agonist human cytotoxic T-cell epitopes of the human papillomavirus type 16 (HPV16) E6/E7.

Tsang KY, Fantini M, Fernando RI, Palena C, David JM, Hodge JW, Gabitzsch ES, Jones FR, Schlom J.

Vaccine. 2017 May 2;35(19):2605-2611. doi: 10.1016/j.vaccine.2017.03.025. Epub 2017 Apr 4.

3.

The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells.

Jochems C, Fantini M, Fernando RI, Kwilas AR, Donahue RN, Lepone LM, Grenga I, Kim YS, Brechbiel MW, Gulley JL, Madan RA, Heery CR, Hodge JW, Newton R, Schlom J, Tsang KY.

Oncotarget. 2016 Jun 21;7(25):37762-37772. doi: 10.18632/oncotarget.9326.

4.

IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib.

Fernando RI, Hamilton DH, Dominguez C, David JM, McCampbell KK, Palena C.

Oncotarget. 2016 Jul 5;7(27):42031-42044. doi: 10.18632/oncotarget.9662.

5.
6.

BCL-2 family protein, BAD is down-regulated in breast cancer and inhibits cell invasion.

Cekanova M, Fernando RI, Siriwardhana N, Sukhthankar M, De la Parra C, Woraratphoka J, Malone C, Ström A, Baek SJ, Wade PA, Saxton AM, Donnell RM, Pestell RG, Dharmawardhane S, Wimalasena J.

Exp Cell Res. 2015 Feb 1;331(1):1-10. doi: 10.1016/j.yexcr.2014.11.016. Epub 2014 Dec 9.

7.

Overexpression of the EMT driver brachyury in breast carcinomas: association with poor prognosis.

Palena C, Roselli M, Litzinger MT, Ferroni P, Costarelli L, Spila A, Cavaliere F, Huang B, Fernando RI, Hamilton DH, Jochems C, Tsang KY, Cheng Q, Lyerly HK, Schlom J, Guadagni F.

J Natl Cancer Inst. 2014 May 9;106(5). pii: dju054. doi: 10.1093/jnci/dju054.

8.

WEE1 inhibition alleviates resistance to immune attack of tumor cells undergoing epithelial-mesenchymal transition.

Hamilton DH, Huang B, Fernando RI, Tsang KY, Palena C.

Cancer Res. 2014 May 1;74(9):2510-9. doi: 10.1158/0008-5472.CAN-13-1894. Epub 2014 Mar 13.

9.
10.

Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine.

Hamilton DH, Litzinger MT, Jales A, Huang B, Fernando RI, Hodge JW, Ardiani A, Apelian D, Schlom J, Palena C.

Oncotarget. 2013 Oct;4(10):1777-90.

11.

The embryonic transcription factor Brachyury blocks cell cycle progression and mediates tumor resistance to conventional antitumor therapies.

Huang B, Cohen JR, Fernando RI, Hamilton DH, Litzinger MT, Hodge JW, Palena C.

Cell Death Dis. 2013 Jun 20;4:e682. doi: 10.1038/cddis.2013.208.

12.

An autocrine loop between TGF-β1 and the transcription factor brachyury controls the transition of human carcinoma cells into a mesenchymal phenotype.

Larocca C, Cohen JR, Fernando RI, Huang B, Hamilton DH, Palena C.

Mol Cancer Ther. 2013 Sep;12(9):1805-15. doi: 10.1158/1535-7163.MCT-12-1007. Epub 2013 Jun 19.

13.

Influence of IL-8 on the epithelial-mesenchymal transition and the tumor microenvironment.

Palena C, Hamilton DH, Fernando RI.

Future Oncol. 2012 Jun;8(6):713-22. doi: 10.2217/fon.12.59. Review.

14.

Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer.

Roselli M, Fernando RI, Guadagni F, Spila A, Alessandroni J, Palmirotta R, Costarelli L, Litzinger M, Hamilton D, Huang B, Tucker J, Tsang KY, Schlom J, Palena C.

Clin Cancer Res. 2012 Jul 15;18(14):3868-79. doi: 10.1158/1078-0432.CCR-11-3211. Epub 2012 May 18.

15.

Cancer vaccines targeting the epithelial-mesenchymal transition: tissue distribution of brachyury and other drivers of the mesenchymal-like phenotype of carcinomas.

Hamilton DH, Litzinger MT, Fernando RI, Huang B, Palena C.

Semin Oncol. 2012 Jun;39(3):358-66. doi: 10.1053/j.seminoncol.2012.02.005. Review.

16.

IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells.

Fernando RI, Castillo MD, Litzinger M, Hamilton DH, Palena C.

Cancer Res. 2011 Aug 1;71(15):5296-306. doi: 10.1158/0008-5472.CAN-11-0156. Epub 2011 Jun 8.

17.

Strategies to target molecules that control the acquisition of a mesenchymal-like phenotype by carcinoma cells.

Palena C, Fernando RI, Litzinger MT, Hamilton DH, Huang B, Schlom J.

Exp Biol Med (Maywood). 2011 May 1;236(5):537-45. doi: 10.1258/ebm.2011.010367. Epub 2011 Mar 22. Review.

18.

The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells.

Fernando RI, Litzinger M, Trono P, Hamilton DH, Schlom J, Palena C.

J Clin Invest. 2010 Feb;120(2):533-44. doi: 10.1172/JCI38379. Epub 2010 Jan 11.

19.

The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy.

Palena C, Polev DE, Tsang KY, Fernando RI, Litzinger M, Krukovskaya LL, Baranova AV, Kozlov AP, Schlom J.

Clin Cancer Res. 2007 Apr 15;13(8):2471-8.

21.

Estrogens down-regulate p27Kip1 in breast cancer cells through Skp2 and through nuclear export mediated by the ERK pathway.

Foster JS, Fernando RI, Ishida N, Nakayama KI, Wimalasena J.

J Biol Chem. 2003 Oct 17;278(42):41355-66. Epub 2003 Aug 6.

22.
23.

Supplemental Content

Loading ...
Support Center